



## IN THE CLAIMS


1. (Original) A novel pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid of the formula




2. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




3. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




4. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




5. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




6. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




7. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




8. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




9. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




10. (Original) A pyrrolo[2, 1-c] [ 1,4] benzodiazepine hybrid as claimed in claim 1 having the formula




11. (Original) A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula V




which comprises reacting a 4- (1H- benzo[d] imidazol-2-yl) phenol of the formula I




with – [4-(n- bromoalkoxy)-5- methoxy-2- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II



in the presence of  $K_2CO_3$  in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {4-(1H- benzo [d] imidazo- 2 yl) phenoxy} alkyl - oxy- 5 methoxy- 2-nitrobenzoyl} pyrrolidine-2- carboxaldehyde diethyl thioacetal III




where "n" is 3 to 5, reducing said compound of formula III with  $SnCl_2 \cdot 2H_2O$  in the presence of organic solvent up to a reflux temperature, isolating the (2S) -N- {n- 4- (1H- benzo [d] imidazo- 2yl)phenoxy}alkyl]-oxy-5-methoxy-2-aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal of the formula IV




where n is 3 to 5 by known methods, reacting the said amino compound of formula IV with conventional deprotecting agents in to produce pyrrolo [2,1-c]1,4] benzodiazepine hybrids of formula V, wherein "n" is as defined above.


12. A process for the preparation of pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula IX




which comprises reacting a 4- [6-4.- methylhexahydro- 1- pyrazinyl)- 1H - benzo [imidazol- 2- yl] phenol VI




with N-[4-(n-bromoalkoxy)-5-methoxy-2-nitrobenzo-yl]pyrrolidine-2-carboxaldehyde diethyl thio acetal of formula II



in the presence of  $K_2CO_3$  in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {n- (4- [6-(4-methylhexahydro-1-pyrazinyl)- 1H- benzo [d] imidazol- 2-yl] phenoxy] alkyl)-oxy-5-methoxy-2-nitrobenzoy pyrrolidine-2- carboxaldehyde diethyl thioacetal VII




where "n" is 3 to 5, reducing said compound of formula VII with  $SnCl_2O$  in the presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n- (4- [6-(4-methylhexahydro-1-pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenoxy] alkyl)-oxy-5-methoxy -2- aminobenzoy) pyrrolidine-2- carboxaldehyde diethyl thioacetal VIII




and reacting the said amino compound of formula VIII with conventional deprotecting agents in to produce pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula IX wherein "n".


13. (Original) A process for the preparation of pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula XIII




which comprises reacting a 4- [6-(4- ethylhexahydro- I-pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenol X




with – [4-(n- bromoalkyloxy)-5- methoxy-2,- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II



in the presence of  $K_2 CO_3$  in organic solvent for a period of 12 to 24 hrs, isolating (2S)- – {n- (4- [6-4- ethylhexahydro-1- pyrazinyl)- H- benzo [d] imidazol-2- yl] phenoxy] alkyl] - oxy- 5- methoxy- 2- nitrobenzoyl) pyrrolidine- 2- carboxaldehyde diethyl thioacetal XI



where "n" is 3 to 5, reducing said compound of formula XI with  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  in the presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n-(4-[6-(4-ethylhexahydro-1-pyrazinyl)-1H - benzo[d] imidazol-2- yl] phenoxy] alkyl)- oxy-5- methoxy-2- aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal XII where n is 3 to 5



and reacting the said amino compound of formula XII with conventional deprotecting agents to produce pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrids of formula XIII wherein "n" is as defined above.

14. (Currently amended) Use of a pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 to 10 for the preparation of medicament useful for treating tumours.

15. (Currently amended) A pharmaceutical composition for use as antitumour agents comprising of an effective amount of a pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 to 10.

16. (Currently amended) A method of treating a mammal which comprises administering an affective amount of a pyrrolo [ 2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 to 10.

17. (Original) A method of treating a mammal, which comprises administering an affective amount of a pharmaceutical composition as claimed in claim 15.